首页> 外文期刊>Nature reviews. Urology >The endocannabinoid system - a target for the treatment of LUTS?
【24h】

The endocannabinoid system - a target for the treatment of LUTS?

机译:内源性大麻素系统-用于治疗LUTS的靶标吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Lower urinary tract symptoms (LUTS) are common in all age groups and both sexes, resulting in tremendous personal suffering and a substantial burden to society. Antimuscarinic drugs are the mainstay of symptom management in patients with LUTS, although their clinical utility is limited by the high prevalence of adverse effects, which often limit patients' long-term adherence to these agents. Data from controversial studies in the 1990s revealed the positive effects of marijuana-based compounds on LUTS, and sparked an interest in the possibility of treating bladder disorders with cannabis. Increased understanding of cannabinoid receptor pharmacology and the discovery of endogenous ligands of these receptors has prompted debate and further research into the clinical utility of exogenous cannabinoid receptor agonists relative to the unwanted psychotropic effects of these agents. Currently, the endocannabinoid system is considered as a potential drug target for pharmacological management of LUTS, with a more favourable adverse event profile than antimuscarinic agents.
机译:下尿路症状(LUTS)在所有年龄段和男女中均很普遍,这会给个人带来巨大的痛苦,并给社会带来沉重的负担。抗毒蕈碱药物是LUTS患者症状管理的主要手段,尽管其不良反应的高发性限制了其临床实用性,而不良反应的高发性常常限制了患者长期坚持使用这些药物。 1990年代有争议的研究数据表明,大麻化合物对LUTS的积极作用,引起了人们对用大麻治疗膀胱疾病的兴趣。对大麻素受体药理学的进一步了解以及这些受体的内源性配体的发现,促使人们对与这些药物的不良精神作用相关的外源性大麻素受体激动剂的临床实用性进行辩论和进一步研究。目前,内源性大麻素系统被认为是LUTS药理学管理的潜在药物靶标,其不良事件概况较抗毒蕈碱剂更为有利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号